377 related articles for article (PubMed ID: 10756965)
21. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
22. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.
Girard T; Treves S; Censier K; Mueller CR; Zorzato F; Urwyler A
Br J Anaesth; 2002 Oct; 89(4):571-9. PubMed ID: 12393358
[TBL] [Abstract][Full Text] [Related]
23. Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript.
Loke JC; Kraev N; Sharma P; Du G; Patel L; Kraev A; MacLennan DH
Anesthesiology; 2003 Aug; 99(2):297-302. PubMed ID: 12883402
[TBL] [Abstract][Full Text] [Related]
24. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
[TBL] [Abstract][Full Text] [Related]
25. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
[TBL] [Abstract][Full Text] [Related]
26. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands.
Islander G; Bendixen D; Ranklev-Twetman E; Ording H
Acta Anaesthesiol Scand; 1996 May; 40(5):579-84. PubMed ID: 8792888
[TBL] [Abstract][Full Text] [Related]
27. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
[TBL] [Abstract][Full Text] [Related]
28. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
[TBL] [Abstract][Full Text] [Related]
29. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia.
Anderson AA; Brown RL; Polster B; Pollock N; Stowell KM
Anesthesiology; 2008 Feb; 108(2):208-15. PubMed ID: 18212565
[TBL] [Abstract][Full Text] [Related]
30. [Diagnosis of disposition for malignant hyperthermia--an updated review based on 1,001 studies].
Olthoff D; Deutrich C; Meinecke CD
Anaesthesiol Reanim; 1997; 22(2):32-40. PubMed ID: 9235003
[TBL] [Abstract][Full Text] [Related]
31. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
[TBL] [Abstract][Full Text] [Related]
32. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
[TBL] [Abstract][Full Text] [Related]
33. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation.
Fagerlund TH; Ording H; Bendixen D; Islander G; Ranklev Twetman E; Berg K
Clin Genet; 1997 Dec; 52(6):416-21. PubMed ID: 9520251
[TBL] [Abstract][Full Text] [Related]
34. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.
Guis S; Figarella-Branger D; Monnier N; Bendahan D; Kozak-Ribbens G; Mattei JP; Lunardi J; Cozzone PJ; Pellissier JF
Arch Neurol; 2004 Jan; 61(1):106-13. PubMed ID: 14732627
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
[TBL] [Abstract][Full Text] [Related]
36. Detection of a novel mutation at amino acid position 614 in the ryanodine receptor in malignant hyperthermia.
Quane KA; Ording H; Keating KE; Manning BM; Heine R; Bendixen D; Berg K; Krivosic-Horber R; Lehmann-Horn F; Fagerlund T; McCarthy TV
Br J Anaesth; 1997 Sep; 79(3):332-7. PubMed ID: 9389851
[TBL] [Abstract][Full Text] [Related]
37. Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.
Keating KE; Giblin L; Lynch PJ; Quane KA; Lehane M; Heffron JJ; McCarthy TV
J Med Genet; 1997 Apr; 34(4):291-6. PubMed ID: 9138151
[TBL] [Abstract][Full Text] [Related]
38. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.
Klingler W; Heiderich S; Girard T; Gravino E; Heffron JJ; Johannsen S; Jurkat-Rott K; Rüffert H; Schuster F; Snoeck M; Sorrentino V; Tegazzin V; Lehmann-Horn F
Orphanet J Rare Dis; 2014 Jan; 9():8. PubMed ID: 24433488
[TBL] [Abstract][Full Text] [Related]
39. Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene.
Matos AR; Sambuughin N; Rumjanek FD; Amoedo ND; Cunha LB; Zapata-Sudo G; Sudo RT
Braz J Med Biol Res; 2009 Dec; 42(12):1218-24. PubMed ID: 19918671
[TBL] [Abstract][Full Text] [Related]
40. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
Gilly H; Musat I; Fricker R; Bittner RE; Steinbereithner K; Kress HG
Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
